Dr. Babiss is CEO of X-Rx Inc., a PPD-majority owned Biotech that focuses on developing innovative early stage drugs in the areas of Oncology, Fibrosis and Autoimmune diseases. Prior to this, Lee was PPD's chief scientific officer and executive vice president of discovery innovation.
Babiss joined PPD in 2010 with more than 21 years of experience in leading R&D efforts in support of drug discovery. He most recently served as president and director of pharmaceutical research for F. Hoffmann-La Roche Ltd., in Basel, Switzerland, where his responsibilities included leading global laboratory functions in chemistry, discovery technologies, therapeutic proteins, non-clinical safety and informatics. He supported drug discovery efforts in oncology, neurosciences, inflammation, virology and metabolism, and was a member of the company’s pharma executive and strategic portfolios committees.
Prior to joining Hoffmann-La Roche, Babiss spent seven years with Glaxo Inc., now GlaxoSmithKline. As vice president of biological sciences and genetics, he had global accountability for developing and implementing the company’s corporate genetics strategy and oncology research efforts focused on the cell cycle.
Babiss earned a doctorate in microbiology from Columbia University and completed his postdoctoral fellowship at The Rockefeller University, where he served as an assistant and associate professor. He has published more than 60 peer-reviewed scientific papers, received numerous fellowship awards and grants, and serves on several scientific advisory committees and boards.
Barrett is a scientist entrepreneur with more than 30 years experience in the biopharmaceutical industry. He is the former CEO and a Director of XenoPort, Inc, a biopharmaceutical-focused company he co-founded in 1999, which was acquired by Arbor Pharmaceutical in 2016. Under Barrett’s guidance, XenoPort advanced five in-house discovered compounds into human trials including mid- to late-stage clinical trials for the treatment of restless legs syndrome (RLS), post-herpetic neuralgia, painful diabetic neuropathy, migraine prophylaxis, alcohol use disorder, spasticity associated with multiple sclerosis and spinal cord injury, gastroesophageal reflux, Parkinson’s disease and psoriasis. Barrett led the company’s efforts that resulted in the FDA approval of HORIZANT (gabapentin enacarbil), the first and only non-dopaminergic drug approved for moderate to severe RLS.
Prior to founding XenoPort, Barrett was Senior Vice President of Research at Affymax Research Institute, where he pioneered the development and use of new drug discovery technology – work that led to 2 FDA-approved medicines. Barrett began his professional career in the neuroscience drug discovery group at Abbott Laboratories. He is currently Executive Chairman of Medikine Inc, and a Director of Concert Pharmaceuticals, Inc. (Nasdaq:CNCE). He is currently Director of the RLS Foundation, a non-profit patient advocacy group and previously served as a Director of the Youth Science Institute, a non-profit focused on K-8 science education. Barrett has co-authored >50 manuscripts from peer-reviewed journals and is an inventor of >50 issued patents in the U.S. He received a BS degree in biology from Bucknell University and a Ph.D degree in pharmacology from Rutgers University.
Dr. Karen Liu is a founding partner of 3E Bioventures Capital, a fund that focuses on venture investments in healthcare related sectors, such as drug, device, diagnostics, increasingly, interdisciplinary innovations at the frontier of BT (Biotech) and IT (information technology). While 3E primarily invests in China, it is also actively exploring cross-border investment opportunities with China angle or can leverage China advantages.
Dr. Karen Liu has been active in China healthcare venture investment since 2006. Her past investments include device companies such as Reach Surgical, Sinomed, diagnostic companies such as Biochain, Micropoint, BGI, drug related companies such as Chiral Quest, Shenogen and mobile health company such as Apricot Forest. Prior to 3E Bioventures, Karen was a partner at Kaiwu Capital in charge of healthcare investment from 2011-2015 and before that, was Managing Director at CRCI Capital from 2007-2011, also in charge of healthcare investment.
In 2006, Karen co-founded Shenogen Pharma, a company developing innovative liver cancer therapeutics, and was its first angle investor. From 2000-2004, she was an entrepreneur and senior team member of 3721, an Internet search company founded by Internet veteran Hongyi Zhou. She helped build up the small internet company and achieved profitability and eventually sold it to Yahoo in early 2004. Karen Liu also worked as a consultant at McKinsey & Company from 1998-2000.
Dr. Liu received her Ph.D degree in Immunology from Harvard University and Master of Medical Sciences degree from Harvard Medical School. She also received her Bachelor of Sciences degree from Cornell University and her EMBA degree from CKGSB – Chungkong Graduate School of Business in China.
Gordon is a biotechnology entrepreneur. Quadriga is an oncology start-up focused on developing targeted anti-cancer drugs. He is currently on the board of directors for Maverix Biomics, a bio-informatics company co-founded by Prof Todd Lowe (UCSC) and is on the board of directors of Ardelyx, Alexza, and 3V Biopharma. From 1997 to 2015, he served in various capacities as Co-Founder and/or CEO of Maxygen, SurroMed, Alexza, and Alavita. From 1991 to 2000, Gordon was CEO and Scientific Director of Affymax Research Institute (acquired by Glaxo in 1995) where he managed the development of novel technologies to accelerate the pace of drug discovery; prior to that he was VP and Director of the Institute for Cancer and Developmental Biology at Syntex Corporation (1986-1991). Gordon received his Ph.D. in the laboratory of Dr. Harold Varmus, before joining the Stanford University School of Medicine, Department of Pharmacology (1978-1987). While on the Stanford faculty he invented technologies for manufacturing of recombinant proteins in mammalian cells, now widely used for production of dozens of therapeutic products and received the John J. Abel Award as the best Pharmacologist in the US under the age of 35. Gordon is an alumnus of Crown College, UC Santa Cruz, 1972.
Peter is a pharmaceutical executive with over 25 years of drug development experience. He is currently President and COO of Quadriga Biosciences. Prior to joining Quadriga, Peter served as President and a member of the Board of Directors of VIVUS Inc, a biopharmaceutical company that develops therapies for the treatment of obesity, diabetes, and urology. Under his leadership, VIVUS obtained four consecutive drug approvals from product inception. Peter built the company’s R&D pipeline through licensing and acquisition. He built and led R&D teams (regulatory, clinical and CMC), created and developed patent portfolio and collaborated with FDA, corporate partners and stakeholders to ensure regulatory approvals for company's pipeline products. He also helped raise over $500M in corporate financing during his 20-year tenure at VIVUS (1993-2012). He has extensive management experience in drug development , corporate/business development, senior executive leadership and board experience in the biopharmaceutical industry. Prior to VIVUS, Peter also held various research and clinical development positions at Genentech and XOMA Corporation.
Peter holds a B.S. in Chemistry from University of California Berkeley and an MBA from Santa Clara University. He has a number of patents approved and pending to his name.